Sappi Casting and Release Announces New Textures Ahead of interzum 2023
1.5.2023 16:00:00 EEST | Business Wire | Press release
Sappi North America, Inc., a leading producer and supplier of diversified paper, packaging products and dissolving wood pulp, has announced it will showcase seven new and recently launched textures from its Arrio finished surface and Ultracast decorative laminate release paper lines during interzum 2023 in Cologne, Germany from May 9-12, 2023.
Visitors to the Sappi booth (#E-048 in Hall 06.1) will be immersed in a sensory experience with surfacing solutions that demonstrate the impact of how we perceive and experience a variety of materials through natural looking design and our sense of touch. Sappi will feature Arrio, a decorative laminate finished surface that delivers remarkable aesthetics, premium haptics and scratch and fingerprint resistance for high-wear surfaces, including the first textured Arrio, called Saffron. Saffron has an undulating woodgrain with a clean visual appeal and rich, deep valleys paired with a soft touch and a very low gloss surface.
Sappi will also display a decorative laminate texture six-pack and a “bio-lab” that will highlight materials such as bio-based leather alternatives whose aesthetics benefit from the use of Sappi release paper. The six-pack will include these new or recently launched textures:
Matte Stipple: This all-over delicate granular design is inspired by plaster effects in the decorative coatings of walls and ceilings. The matte effect visually softens the look of the texture and adds warmth to the chalky aesthetics. The gritty/sandy haptics create a satisfying touch experience.
Lunaris: With its elevated concrete look, Lunaris expresses the spirit of surface patterns eroded over time, celebrating the beauty of naturally created texture. The matte, porous finish and the gentle touch that characterize Lunaris are central to high-end interiors or environments with calming and restorative effects.
Koa: Koa's curly, wavy pattern is arguably one of the most beautiful woodgrain textures in Sappi’s catalog. The unique figuring, micro-contrast and haptic qualities make it stand out with an incredible optical reflectance that gives an almost 3D quality to the surface.
Kenwood CD Kenwood CD (CD=cross direction) is a modern and sophisticated version of Sappi's popular Kenwood design, aimed at the medium-high-end door market. Kenwood CD features a unique cross-direction orientation ideal for contemporary kitchen and furniture design.
Cayenne: Cayenne is a natural, fresh and trendy wood texture inspired by a refined linear Italian walnut surface. The flow of the dark veins and the softness of the touch are stand-out features. The "wow-effect" of Cayenne is an elegant, smoky matte finish.
Bond: Bond rounds up every elevated laminate collection with the warmth and coziness of a textile finish. The allover matte appeal is enhanced by the subtle sheen of silky threads spreading through the fabric. Bond is symbolic for the beauty of timeless design.
Sappi creates forward-looking products and textures by leveraging state-of-the-art technology from its innovation center in Westbrook, Maine, drawing design inspiration from around the world. Sappi’s extensive library includes a product range of over 70 textures for worktops, kitchen counters and cabinets, flooring, wall paneling and other laminate applications. This wide range of textures, coating and converting capabilities make the company the largest supplier of casting and release papers in the world.
“Texture, haptics, and function are important attributes to the surfaces in our lives, and we’re constantly seeking innovative ways to translate new textures through Arrio finished surfaces and our casting and release papers. We know that what we see and touch shape what we feel,” said Mark Hittie, Director, Release Business Strategy, Sappi North America. “The featured textures in our Ultracast line draw from real-world inspirations to provide authentic, tangible experiences designed with purpose. We’re proud to offer superior textures with unmatched quality and performance for brands that put the consumer experience first.”
To learn more about Sappi, please visit www.sappirelease.com.
About Sappi North America, Inc.
Sappi North America, Inc., headquartered in Boston, is a market leader in converting wood fiber into superior products that customers demand worldwide. Our four diversified businesses – high-quality Graphic Papers, Dissolving Pulp, Packaging, and Specialty Papers deliver premium products and services with consistent quality and reliability. Our high-quality Coated Printing Papers are used for premium magazines, catalogs, books, direct mail and high-end print advertising. We are a leading manufacturer of Dissolving Pulp, which is used in a wide range of products, including textile fibers and household goods. We deliver sustainable Packaging and Specialty Papers for luxury packaging and folding carton applications with our single-ply packaging brands and for the food and label industries with our specialty papers. We are one of the world's leading suppliers of Casting and Release Papers with lines for the automotive, fashion and engineered films industries.
Sappi North America is a subsidiary of Sappi Limited (JSE), a global company headquartered in Johannesburg, South Africa, with more than 12,000 employees and manufacturing operations on three continents in seven countries and customers in over 150 countries. www.sappi.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230501005072/en/
Contact information
Press
Peter A. Steele
Sappi North America
+1 617 423 5409
Peter.Steele@sappi.com
Christy Reiss
Matter Communications
+1 617 502 6543
Sappi@matternow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
